Lexicon Pharmaceuticals management to join Nasdaq HQ fireside chat

Lexicon Pharmaceuticals management to join Nasdaq HQ fireside chat
Lexicon joins BioConnect at Nasdaq

Lexicon Pharmaceuticals announced it will participate in the HCWCO BioConnect Investor Conference this week.

The company’s management team is scheduled to take part in a fireside chat on May 19 at Nasdaq headquarters in New York City, offering insights into its strategic initiatives and engaging with the investor community.

Lexicon is advancing late-stage clinical programs, including the SONATA-HCM Phase 3 trial of its SGLT1/SGLT2 inhibitor for hypertrophic cardiomyopathy. The company also recently presented Phase 2b data at AAN 2026 supporting a 10 mg dose for diabetic peripheral neuropathic pain. These developments come as management prepares to outline strategic initiatives to investors in New York.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.